Adalvo announces successful DCP Submission for Desogestrel + Ethinylestradiol (0.15mg+0.02mg) film coated tablets
We are pleased to announce our successful DCP submission for Desogestrel+Ethinylestradiol (0.15mg+0.02mg) film-coated tablets.
This accomplishment enables Adalvo to provide multiple treatment options to both partners and patients.
Our Desogestrel+Ethinylestradiol 0.15mg/0.02mg film-coated tablets were developed in collaboration with one of our strategic partners, based on the reference brand Mercilon film-coated tablets. The product is a low-dose contraceptive used by women to prevent pregnancy.
According to IQVIA, Desogestrel+Ethinylestradiol (0.15mg+0.02mg) generated approximately $85mn in global sales in 2022.
Building on this accomplishment, Adalvo continues to expand their Women's Health portfolio. As a distinguished player in this domain, we are delighted to offer a wide range of products, as outlined below:
Cyproterone + Ethinylestradiol, 2 mg + 0.035 mgDesogestrel, 75 mcgDesogestrel +...
Adalvo Limited
-
MT
-
2020On CPHI since
-
1Certificates
-
100 - 249Employees
Other Content from Adalvo Limited (1)
-
News Adalvo CEO, Anil Okay nominated as finalist for CEO of the year award
Adalvo are honored to have been recognized by CPhI Pharma, where our CEO, Anil Okay, has been nominated as a finalist for the CEO of the Year Award!
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance